Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 May;7(3):131-40.
doi: 10.1177/1756283X13515825.

Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential

Catherine Stedman  1
Affiliations
Review

Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential

Catherine Stedman. Therap Adv Gastroenterol. 2014 May.

Abstract

Treatment of chronic hepatitis C (HCV) is currently undergoing a significant change. Traditional interferon-based therapy has been limited by both efficacy and tolerability, and many direct acting antiviral (DAA) drugs are emerging. Sofosbuvir (GS-7977) is a HCV NS5B nucleotide polymerase inhibitor that has now been evaluated extensively in phase II and III interferon-free clinical trials. The focus of this review is on the clinical potential of sofosbuvir in the treatment of HCV. Sofosbuvir has a pan-genotypic effect on HCV, although viral genotype-specific differences in sustained virological response (SVR) have emerged in phase III clinical trials. Sofosbuvir has been studied both as dual therapy with ribavirin and also as triple therapy with either NS5A inhibitors or a protease inhibitor. High rates of SVR have been reported with these interferon-free combinations, particularly with genotypes 1 and 2, and the safety profile has been very favourable in both cirrhotic and noncirrhotic patients, without issues of viral resistance. Interferon-free, once-daily treatment of HCV is now becoming a reality.

Keywords: direct acting antivirals; hepatitis C; sofosbuvir.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: Disclosures: Grant/Research Gilead; Advisory Board - Janssen.

References

    1. Chen J., Florian J., Carter W., Fleischer R., Hammerstrom T., Jadhav P., et al. (2013) Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 144: 1450–1455 - PubMed
    1. Cornpropst M., Denning J., Clemons D., Marbury T., Alcorn H., Smith W., et al. (2012) The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of PSI-7977. J Hepatol 56(Suppl. 2): Abstract 1101
    1. Denning J., Cornpropst M., Clemons D., Fang L., Sale M., Berrey M., et al. (2011) Lack of effect of the nucleoside analog polymerase inhibitor PSI-7977 on methadone PK and PD. Hepatology 54(4): Abstract 372. - PubMed
    1. Fontaine H., Hezode C., Dorival C., Larrey D., Zoulim F., De Ledinghen V., et al. (2013) SVR12 rates and safety of triple therapy including telaprevir or boceprevir in 221 cirrhotic non responders treated in the French early access program (ANRS C020-CUPIC). J Hepatol 58(S25–S44): A60
    1. Fontana R., Hughes E., Bifano M., Appelman H., Dimitrova D., Hindes R., et al. (2013) Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 13: 1601–1605 - PubMed

LinkOut - more resources